• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a
The Acute Respiratory Syndrome by Corona Virus 2 (SARS-CoV-2), first discovered in December 2019 in Wuhan/China, is causing a worldwide pandemic with potentially lethal implications on an individual basis, and, on the large scale bringing the health care systems and the economy to its limits. The mortality rate of this Coronavirus induced Disease, COVID-19, has been estimated by the World Health Organization (WHO) to be 3.7%, which is more than 10-fold higher than the mortality

Major Drugs for treatment of COVID19

Posted by pharmintel on April 12, 2020

Category: Blog
Pharmintel has compiled the list of top drugs which are in trial for the treatment of COVID19 considering the resent surges of treatment for COVID19 & to provide a one stop solution to all your data needs. CompanyDrug NameGeneric NamePhaseType Fujifilm Toyama Chemical Avigan Favipiravir Phase III RNA-dependent RNA polymerases (RdRps) Inhibitor Abbivie Kaletra® (also marketed as Aluvia) lopinavir/ritonavir Phase Not Available HIV-1 protease inhibitor / Mechanism of Action Sanofi & Regeneron Kevzara® sarilumab Phase 2/3
Standard protocols are very crucial for safeguarding human health. Before approving and allowing the use of a CORONAVIRUS (COVID-19) vaccine for trial in humans, regulators should evaluate safety and efficacy measures with a range of virus strains and in more than one animal model starting from lab mice to a monkey, etc. They should also have enough preclinical evidence that supports the experimental vaccines for preventing the infection, which means that we will probably have

Clinical development for COVID 19 in 2020

Posted by pharmintel on March 24, 2020

Category: Blog
A Phase 1 of clinical trial has begun at Kaiser Permanente Washington Health Research Institute in Seattle to evaluate an investigational vaccine designed to protect against the novel Coronavirus disease (COVID-19) The NIAID, a part of the National Institutes of Health, is funding the trial. The study is just to analyze the safety level by evaluating different doses of the experimental vaccine and its ability to induce an immune response in patients. It is the first
+91 9643310025, 9643312749
© 2020 Pharmintel